



CryoLife to Present at Upcoming Investor Conferences in New York

November 3, 2011

ATLANTA, Nov. 3, 2011 /PRNewswire via COMTEX/ -- **CryoLife, Inc.** (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that Steven G. Anderson, president and chief executive officer of CryoLife, Inc., is scheduled to present at the upcoming Lazard Capital Markets Eighth Annual Healthcare Conference on Tuesday, November 15, 2011 at 3:00 pm ET in New York City.

CryoLife is also scheduled to present at the Stephens, Inc Fall Investment Conference on Wednesday, November 16, 2011. Steven G. Anderson will present at 11:30 am ET in New York City.

CryoLife's live presentations may be accessed through its Web site, <http://www.cryolife.com/>, on the Investor Relations page. An archived copy of the presentations will be available for 90 days on the same Web site.

About CryoLife

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the U.S. and Canada. CryoLife's CryoValve[®] SG pulmonary heart valve, processed using CryoLife's proprietary SynerGraft[®] technology, has FDA 510(k) clearance for the replacement of diseased, damaged, malformed, or malfunctioning native or prosthetic pulmonary valves. CryoLife's CryoPatch[®] SG pulmonary cardiac patch has FDA 510(k) clearance for the repair or reconstruction of the right ventricular outflow tract (RVOT), which is a surgery commonly performed in children with congenital heart defects, such as Tetralogy of Fallot, Truncus Arteriosus, and Pulmonary Atresia. CryoPatch SG is distributed in three anatomic configurations: pulmonary hemi-artery, pulmonary trunk, and pulmonary branch. CryoLife's BioGlue[®] Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair and was recently approved in Japan for use in the repair of aortic dissections. CryoLife, through its subsidiary Cardiogenesis Corporation, specializes in the treatment of cardiovascular disease and the sale of devices that treat severe angina. Its market leading FDA-approved Holmium: YAG laser system and single use fiber-optic delivery systems are used to perform a surgical procedure known as Transmyocardial Revascularization (TMR). CryoLife distributes PerClot[®], an absorbable powder hemostat, in the European Community. CryoLife's BioFoam^(TM) Surgical Matrix is CE marked in the European Community for use as an adjunct in the sealing of abdominal parenchymal tissues (liver and spleen) when cessation of bleeding by ligature or other conventional methods is ineffective or impractical.

For additional information about the company, visit CryoLife's Web site: <http://www.cryolife.com/>.

Contacts:

CryoLife

D. Ashley Lee

Executive Vice President, Chief Financial Officer and Chief

Operating Officer

Phone: 770-419-3355

The Ruth Group

Nick Laudico / Zack Kubow

646-536-7030 / 7020

nlaudico@theruthgroup.com

zkubow@theruthgroup.com

SOURCE CryoLife, Inc.